Compare PRO & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRO | MNMD |
|---|---|---|
| Founded | 1985 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 960.2M |
| IPO Year | 2007 | N/A |
| Metric | PRO | MNMD |
|---|---|---|
| Price | $23.25 | $12.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $24.54 | ★ $25.78 |
| AVG Volume (30 Days) | 1.2M | ★ 1.5M |
| Earning Date | 10-27-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $351,682,000.00 | N/A |
| Revenue This Year | $10.50 | N/A |
| Revenue Next Year | $10.86 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.92 | N/A |
| 52 Week Low | $13.61 | $4.70 |
| 52 Week High | $29.84 | $14.43 |
| Indicator | PRO | MNMD |
|---|---|---|
| Relative Strength Index (RSI) | 76.65 | 58.17 |
| Support Level | $23.06 | $12.19 |
| Resistance Level | $23.20 | $13.45 |
| Average True Range (ATR) | 0.05 | 0.70 |
| MACD | -0.04 | 0.11 |
| Stochastic Oscillator | 95.24 | 82.75 |
Pros Holdings Inc provides software solutions that optimize shopping and selling experiences for both business-to-business and business-to-consumer companies across industry verticals in more than nearly 80 countries. Its PROS Platform is designed to help businesses create, optimize and market available offers and handle orders through both first- and third-party digital channels. The firm generates key revenue form the United States of America, Germany, The rest of Europe, Africa, Asia-Pacific, and Middle East regions.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).